Advertisement

Selasa, 23 April 2019

$10 trillion custodian Northern Trust is exploring shutting off external email for thousands of its employees as it tries to thwart cyber threats

One of the custodian bank's tactics includes a new executive role focused on data security for a 30-year company veteran.
April 23, 2019   |   View Online »
 
$10 trillion custodian Northern Trust is exploring shutting off external email for thousands of its employees as it tries to thwart cyber threats

$10 trillion custodian Northern Trust is exploring shutting off external email for thousands of its employees as it tries to thwart cyber threats

Meghan Morris | One of the custodian bank's tactics includes a new executive role focused on data security for a 30-year company veteran.

Read More »
Top cannabis CEOs say Canopy Growth's $3.4 billion purchase of pot cultivator Acreage 'shakes the foundation of what has been true' and will spur a cannabis M&A boom

Top cannabis CEOs say Canopy Growth's $3.4 billion purchase of pot cultivator Acreage 'shakes the foundation of what has been true' and will spur a cannabis M&A boom

Jeremy Berke | "Canopy has just gone bigger than everybody, as they do — they don't take small swings," a cannabis CEO told Business Insider.

Read More »
$4 billion Credit Karma's CEO reveals how a single meeting in 2008 saved the company from going under

$4 billion Credit Karma's CEO reveals how a single meeting in 2008 saved the company from going under

Dan DeFrancesco | Kenneth Lin explained how critical a meeting with a TransUnion executive was during Credit Karma's early days.

Read More »
One of America's top-ranked wealth managers details a huge strategic change she made after 20 years of success — and says she'd do it again in a heartbeat

One of America's top-ranked wealth managers details a huge strategic change she made after 20 years of success — and says she'd do it again in a heartbeat

Marley Jay | Rebecca Rothstein, who manages $3.8 billion for ultrarich investors, says her firm made a huge shift toward exchange-traded funds in the past year.

Read More »
iM Global has taken a stake in a top-performing equity business, as it looks to put its remaining $400 million to work

iM Global has taken a stake in a top-performing equity business, as it looks to put its remaining $400 million to work

Meghan Morris | The deal comes amid a hot time for M&A in asset management, with deal value up 72% last year, according to PwC.

Read More »
A former Starbucks HR exec shares the single job-interview question that predicts success better than a résumé

A former Starbucks HR exec shares the single job-interview question that predicts success better than a résumé

Shana Lebowitz | Asking interview questions about challenging work experiences helps Traci Wilk discern whether a candidate is willing to learn from their mistakes.

Read More »
Here's why companies like Google, Square, and Atlassian are sprinting to use Kotlin, the fastest-growing programming language according to GitHub

Here's why companies like Google, Square, and Atlassian are sprinting to use Kotlin, the fastest-growing programming language according to GitHub

Rosalie Chan | Companies like Google, Square, Atlassian, and Capital One are increasingly using Kotlin, the fastest-growing programming language according to GitHub.

Read More »
Why Wall Street is worried that Apple is getting left behind in the 5G arms race

Why Wall Street is worried that Apple is getting left behind in the 5G arms race

Charlie Wood | Many industry analysts predict a tough time for Apple in the race to embrace 5G wireless, but this won't necessarily harm the company long term.

Read More »
The JPMorgan, Amazon, and Berkshire Hathaway healthcare venture is setting up shop in NYC to snag top tech workers

The JPMorgan, Amazon, and Berkshire Hathaway healthcare venture is setting up shop in NYC to snag top tech workers

Lydia Ramsey | The new company is opening a New York office near Union Square in Manhattan and plans to hire for technology and engineering roles.

Read More »
A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease

A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease

Erin Brodwin | Insitro and Gilead are teaming up to create drugs for a liver disease affecting millions. The startup is backed by Jeff Bezos and Andreessen Horowitz.

Read More »

Share This Email

  

Read Business Insider On The Go

App Store    Google Play



Email sent to: ipat39@gmail.com

Manage your email preferences   |   Unsubscribe

Terms of Service   |   Privacy Policy

Business Insider. 150 Fifth Ave, New York, NY 10011
Powered By SailthrU

Tidak ada komentar:

Posting Komentar